Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2013-08-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
独立董事关于公司有关事项所发表的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion letter regarding various company matters including the use of raised funds, nomination of board candidates, independent director remuneration, change of audit firm, use of idle funds for bank wealth management products, and guarantees and related party fund occupation. It references compliance with laws and regulations, and provides independent opinions rather than presenting full financial statements or detailed financial results. The document length is short (1843 characters) and it is a formal opinion letter rather than a full report. This type of document is typically classified as a Regulatory Filing (RNS) because it does not contain comprehensive financial data or constitute a full audit or annual report, but is a regulatory disclosure related to governance and compliance matters.
2013-08-19 Chinese
第二届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 18th meeting of the second board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approval of the 2013 semi-annual report, nomination of board candidates, changes in audit firms, and other corporate governance matters. It contains detailed information about board members and independent directors, their qualifications, and related opinions. The document is not the semi-annual report itself but a board meeting resolution announcement. It also includes nominations for the new board and changes in audit firms, which are typical of board/management information disclosures. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (7782 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive board meeting resolution document.
2013-08-19 Chinese
独立董事候选人声明（韩文君）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, independence, compliance with relevant laws and regulations, and absence of conflicts of interest. There are no financial statements, earnings data, or report summaries. The document is a formal declaration related to board/management information, specifically about an independent director candidate's qualifications and compliance. This fits the category of Board/Management Information (MANG). The document length is 4353 characters, which is sufficient for a detailed declaration but not a full report. There is no indication that this is an announcement of a report or a certification letter. Therefore, the best classification is MANG with high confidence.
2013-08-19 Chinese
第二届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approval of the 2013 semi-annual report and a special report on the use of raised funds, as well as nomination of candidates for the next Supervisory Board. The document references the 2013 semi-annual report and related financial reports but does not contain the actual financial statements or detailed financial data itself. It is a meeting resolution and announcement rather than the report itself. The document length is 2835 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of meeting resolutions and related disclosures that do not fit into other specific categories like Interim Report or Annual Report.
2013-08-19 Chinese
2013年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2013 半年度报告全文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2013 Semi-Annual Report Full Text." It contains detailed financial data, management discussion, business analysis, investment status, and other comprehensive information typical of a semi-annual or interim financial report. The document includes actual financial statements, accounting data, and analysis for the first half of 2013. It is not a brief announcement or a certification letter but a full report covering a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2013
2013-08-19 Chinese
2013年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the status of funds raised through a public offering, including the amount raised, usage, management, and changes in the use of the raised funds. It includes detailed financial figures, project progress, and investment outcomes as of June 30, 2013. The document is titled as a "2013 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds" and contains substantive financial data and analysis related to the use of capital raised by the company. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not an announcement of a report but the report itself, given its length and detailed content. Therefore, the appropriate classification is CAP.
2013-08-19 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.